What is MacroGenics?
MacroGenics operates as a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of innovative monoclonal antibody-based therapeutics. By leveraging advanced protein engineering and proprietary technology platforms, the company has successfully cultivated a diverse pipeline of product candidates. Its market position is further solidified by a series of strategic collaborations with global pharmaceutical and biotechnology leaders, which serve to validate its scientific approach and accelerate the commercialization of its oncology-focused portfolio.
How much funding has MacroGenics raised?
MacroGenics has raised a total of $559M across 10 funding rounds:
Series D
$25M
Grant
$9.8M
Stock Offering
$83.8M
Stock Offering
$76.7M
Stock Offering
$141M
Stock Offering
$23.6M
Stock Offering
$110M
Series D (2008): $25M featuring Red Abbey Venture Partners, Innovis Investments, OrbiMed, CIDC, Arcus Ventures, Alexandria, Mitsubishi UFJ, Alta Partners, InterWest Partners, Ventures West, Eli Lilly and Company, TPG Ventures, Nextech Venture, and RiverVest
Grant (2010): $9.8M backed by National Institutes of Health
Stock Issuance/Offering (2013): $83.8M with participation from Undisclosed
Stock Issuance/Offering (2014): $76.7M led by Undisclosed
Stock Issuance/Offering (2015): $141M supported by Undisclosed
Stock Issuance/Offering (2017): $23.7M featuring Undisclosed
Stock Issuance/Offering (2018): $110M backed by Undisclosed
Key Investors in MacroGenics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation cycles.
MPM Capital
MPM BioImpact manages early-stage venture funds and private impact funds, specializing in converting scientific research into viable therapeutic solutions for patients.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for MacroGenics?
Looking ahead, MacroGenics is positioned to leverage its historical capital base to drive late-stage clinical trials and expand its therapeutic reach. The company's strategic focus remains on the refinement of its antibody-based platforms, with an emphasis on achieving regulatory milestones that will enhance its competitive standing. By maintaining a disciplined approach to research and development, MacroGenics aims to translate its scientific innovations into tangible patient outcomes, while simultaneously exploring new partnership opportunities to maximize the value of its intellectual property and clinical assets.
See full MacroGenics company page
